Close Menu

NEW YORK (GenomeWeb) – Qiagen is taking aim at the high-throughput, high-volume molecular diagnostics market through its recently announced partnership and merger agreement with molecular diagnostics developer NeuMoDx.

The deal calls for Qiagen to initially distribute the NeuMoDx N288 and NeuMoDx N96 fully integrated molecular testing platforms in Europe and other ex-US markets, while Ann Arbor, Michigan-based NeuMoDx will continue to market its systems and tests in its home country.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.